Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Eris Life Sciences to...

    Eris Life Sciences to acquire Strides India branded formulation business for Rs 500 crore: Report

    Written by Ruby Khatun Khatun Published On 2017-11-18T16:31:06+05:30  |  Updated On 18 Aug 2021 3:41 PM IST

    MUMBAI: Eris Life Sciences is going to acquire Stride Shasun India branded formulations business as the company has agreed to sell it for Rs 500 crore a recent report in the Economic Times States.


    The daily has reported that a formal announcement for the same is going to be made on Monday. The company is joining a select league of Indian pharmaceuticals firms exiting the domestic market to focus on more lucrative international business.


    Multiple people with direct knowledge of the matter told ET that the transaction involves domestic brands of Strides while manufacturing facilities of the firm will continue to support its global generic businesses. Domestic brands of Stride Shasun contributed Rs 180 crore to the top line in FY17.


    The sole advisor to the transaction is MAPE Advisory Group.


    The company, Strides Shasun has eight pharmaceutical plants in India, mostly situated in the southern and western part of India. The transaction is in line with many Indian pharmaceutical companies selling their domestic business to either rivals or global firms to focus more on the lucrative international market.


    Earlier this month, Unichem Labs sold its India business to Torrent Pharma for Rs 3,600 crore.


    Grown mostly through acquisitions, Strides has made a series of buyouts including CNS business of erstwhile Ranbaxy and brands portfolio of Johnson & Johnson, besides taking a controlling stake in probiotics company Medispan, which was a part of the Chennai-based Shriram Group reports ET.


    Eris Life Sciences is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as cardiovascular; anti-diabetes; vitamins; gastroenterology and gynaecology with the focus on developing, manufacturing and marketing products which are linked to lifestyle-related disorders that are chronic in nature and are treated by superspecialist and specialist doctors.

    acquireAcquisitionadvisorbusinessdomestic brandsEris Life SciencesIndiaindian pharma newsJohnson and JohnsonMAPE Advisory Grouppharma newspharma news indiaRanbaxyStridesStrides ShasunTorrent PharmatransactionUnichem Labs
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok